



Clinical trial results:

A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF)

Summary

| | |
|--------------------------|-------------------------------|
| EudraCT number | 2016-002278-11 |
| Trial protocol | DE HU CZ NL ES BE GB LT IT RO |
| Global end of trial date | 26 April 2021 |

Results information

| | |
|--------------------------------|--------------|
| Result version number | v1 (current) |
| This version publication date | 06 May 2022 |
| First version publication date | 06 May 2022 |

Trial information

Trial identification

| | |
|-----------------------|----------|
| Sponsor protocol code | 1245.110 |
|-----------------------|----------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT03057951 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | Boehringer Ingelheim |
| Sponsor organisation address | Binger Straße 173, Ingelheim am Rhein, Germany, 55216 |
| Public contact | Boehringer Ingelheim, Call Centre, Boehringer Ingelheim, 001 018002430127, clintrriage.rdg@boehringer-ingelheim.com |
| Scientific contact | Boehringer Ingelheim, Call Centre, Boehringer Ingelheim, 001 18002430127, clintrriage.rdg@boehringer-ingelheim.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|---------------|
| Analysis stage | Final |
| Date of interim/final analysis | 01 June 2021 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 26 April 2021 |
| Global end of trial reached? | Yes |
| Global end of trial date | 26 April 2021 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

The objective of this event-driven trial was to demonstrate superiority of empagliflozin 10 mg versus placebo in patients with symptomatic, chronic heart failure and preserved left ventricular ejection fraction (LVEF >40%) under stable treatment of heart failure symptoms.

Protection of trial subjects:

Only subjects that met all the study inclusion and none of the exclusion criteria were to be entered in the study. All subjects were free to withdraw from the clinical trial at any time for any reason given. Close monitoring of all subjects was adhered to throughout the trial conduct. Rescue medication was allowed for all patients as required.

Background therapy: -

Evidence for comparator: -

| | |
|---|---------------|
| Actual start date of recruitment | 27 March 2017 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|-------------------------|
| Country: Number of subjects enrolled | Argentina: 825 |
| Country: Number of subjects enrolled | Australia: 233 |
| Country: Number of subjects enrolled | Belgium: 61 |
| Country: Number of subjects enrolled | Brazil: 2038 |
| Country: Number of subjects enrolled | Canada: 393 |
| Country: Number of subjects enrolled | China: 255 |
| Country: Number of subjects enrolled | Colombia: 455 |
| Country: Number of subjects enrolled | Czechia: 845 |
| Country: Number of subjects enrolled | Germany: 569 |
| Country: Number of subjects enrolled | Hungary: 610 |
| Country: Number of subjects enrolled | India: 181 |
| Country: Number of subjects enrolled | Italy: 223 |
| Country: Number of subjects enrolled | Japan: 526 |
| Country: Number of subjects enrolled | Korea, Republic of: 151 |
| Country: Number of subjects enrolled | Mexico: 318 |
| Country: Number of subjects enrolled | Netherlands: 225 |
| Country: Number of subjects enrolled | Poland: 1588 |
| Country: Number of subjects enrolled | Romania: 234 |
| Country: Number of subjects enrolled | Singapore: 36 |

| | |
|--------------------------------------|---------------------|
| Country: Number of subjects enrolled | South Africa: 365 |
| Country: Number of subjects enrolled | Spain: 160 |
| Country: Number of subjects enrolled | United Kingdom: 53 |
| Country: Number of subjects enrolled | United States: 1239 |
| Worldwide total number of subjects | 11583 |
| EEA total number of subjects | 4515 |

Notes:

Subjects enrolled per age group

| | |
|---|------|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 3258 |
| From 65 to 84 years | 7755 |
| 85 years and over | 570 |

Subject disposition

Recruitment

Recruitment details:

A randomised, double-blind trial to demonstrate superiority of empagliflozin versus placebo in patients with symptomatic, chronic heart failure and preserved left ventricular ejection fraction (LVEF>40%) under stable treatment of heart failure symptoms.

Pre-assignment

Screening details:

Patients were included in the trial after they had signed the informed consent form (ICF). Patients who met all of the inclusion and none of the exclusion criteria were to be included in the trial. All patients were informed that they were free to withdraw their consent at any time during the trial without penalty or prejudice.

Period 1

| | |
|------------------------------|---|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Data analyst, Assessor |

Blinding implementation details:

Patients, investigators and everyone involved in trial conduct or analysis or with any other interest in this double-blind trial remained blinded with regard to the randomised treatment assignments until after database lock.

Arms

| | |
|------------------------------|---------|
| Are arms mutually exclusive? | Yes |
| Arm title | Placebo |

Arm description:

1 film-coated tablet of matching placebo was administered orally once daily in patients with chronic heart failure with preserved ejection fraction (HFpEF).

| | |
|--|--------------------|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Film-coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

1 film-coated tablet of matching placebo was administered orally once daily in patients with chronic heart failure with preserved ejection fraction (HFpEF).

| | |
|------------------|---------------------|
| Arm title | 10 mg Empagliflozin |
|------------------|---------------------|

Arm description:

1 film-coated tablet of 10 milligram (mg) of empagliflozin was administered orally once daily in patients with chronic heart failure with preserved ejection fraction (HFpEF).

| | |
|--|--------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Jardiance® |
| Investigational medicinal product code | |
| Other name | BI 10773 |
| Pharmaceutical forms | Film-coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

1 film-coated tablet of 10 milligram (mg) of empagliflozin was administered orally once daily in patients with chronic heart failure with preserved ejection fraction (HFpEF).

| Number of subjects in period 1^[1] | Placebo | 10 mg Empagliflozin |
|---|---------|---------------------|
| Started | 2991 | 2997 |
| Treated | 2989 | 2996 |
| Completed | 2046 | 2051 |
| Not completed | 945 | 946 |
| Adverse event, serious fatal | 244 | 249 |
| Patient moved away | 3 | 4 |
| Medical advice | 6 | 2 |
| Study drug stopped, reason missing | 6 | 1 |
| Not treated | 2 | 1 |
| Patient decision | 5 | 2 |
| Adverse event, non-fatal | 309 | 326 |
| Patient refusal to continue, not due to AE | 304 | 284 |
| Other reason than stated above | 23 | 29 |
| Investigator decision | 2 | - |
| Lost to follow-up | 6 | 16 |
| Due to Covid-19 Pandemic | 2 | 8 |
| Not attending study visits | 3 | - |
| Protocol deviation | 30 | 24 |

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 11583 patients were enrolled worldwide, whereof actually 5988 patients were included in this trial.

Baseline characteristics

Reporting groups

| | |
|--|---------------------|
| Reporting group title | Placebo |
| Reporting group description: | |
| 1 film-coated tablet of matching placebo was administered orally once daily in patients with chronic heart failure with preserved ejection fraction (HFpEF). | |
| Reporting group title | 10 mg Empagliflozin |
| Reporting group description: | |
| 1 film-coated tablet of 10 milligram (mg) of empagliflozin was administered orally once daily in patients with chronic heart failure with preserved ejection fraction (HFpEF). | |

| Reporting group values | Placebo | 10 mg Empagliflozin | Total |
|---|---------|---------------------|-------|
| Number of subjects | 2991 | 2997 | 5988 |
| Age categorical | | | |
| Randomised Set (RS), including all randomised patients. | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 605 | 594 | 1199 |
| From 65-84 years | 2180 | 2225 | 4405 |
| 85 years and over | 206 | 178 | 384 |
| Age Continuous | | | |
| Randomised Set (RS), including all randomised patients. | | | |
| Units: years | | | |
| arithmetic mean | 71.9 | 71.8 | |
| standard deviation | ± 9.6 | ± 9.3 | - |
| Sex: Female, Male | | | |
| Randomised Set (RS), including all randomised patients. | | | |
| Units: Participants | | | |
| Female | 1338 | 1338 | 2676 |
| Male | 1653 | 1659 | 3312 |
| Race (NIH/OMB) | | | |
| Randomised Set (RS), including all randomised patients. | | | |
| Units: Subjects | | | |
| American Indian or Alaska Native | 104 | 90 | 194 |
| Asian | 411 | 413 | 824 |
| Native Hawaiian or Other Pacific Islander | 19 | 14 | 33 |
| Black or African American | 125 | 133 | 258 |
| White | 2256 | 2286 | 4542 |
| More than one race | 75 | 60 | 135 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Ethnicity (NIH/OMB) | | | |

| Randomised Set (RS), including all randomised patients. | | | |
|---|------|------|------|
| Units: Subjects | | | |
| Hispanic or Latino | 754 | 770 | 1524 |
| Not Hispanic or Latino | 2236 | 2227 | 4463 |
| Unknown or Not Reported | 1 | 0 | 1 |

End points

End points reporting groups

| | |
|--|---------------------|
| Reporting group title | Placebo |
| Reporting group description: | |
| 1 film-coated tablet of matching placebo was administered orally once daily in patients with chronic heart failure with preserved ejection fraction (HFpEF). | |
| Reporting group title | 10 mg Empagliflozin |
| Reporting group description: | |
| 1 film-coated tablet of 10 milligram (mg) of empagliflozin was administered orally once daily in patients with chronic heart failure with preserved ejection fraction (HFpEF). | |

Primary: Time to first event of adjudicated cardiovascular (CV) death or adjudicated Hospitalisation for Heart Failure (HHF)

| | |
|--|---|
| End point title | Time to first event of adjudicated cardiovascular (CV) death or adjudicated Hospitalisation for Heart Failure (HHF) |
| End point description: | |
| Composite primary endpoint - Time to first event of adjudicated CV death or adjudicated HHF in patients with Heart Failure with preserved Ejection Fraction (HFpEF). The incidence rate per 100 patient years (pt-yrs) is presented and calculated as followed: Incidence rate per 100 pt-yrs = $100 * \text{number of patients with event} / \text{time at risk [years]}$. Time at risk [years] = Sum of time at risk [days] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier. | |
| Randomised Set (RS), including all randomised patients. | |
| End point type | Primary |
| End point timeframe: | |
| From randomization until completion of the planned treatment phase, up to 1403 days. | |

| End point values | Placebo | 10 mg Empagliflozin | | |
|---|---------------------|---------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 2991 | 2997 | | |
| Units: Patients with event/100 pt-yrs at risk | | | | |
| number (confidence interval 95%) | 8.67 (7.94 to 9.44) | 6.86 (6.22 to 7.54) | | |

Statistical analyses

| | |
|--|-------------------------------|
| Statistical analysis title | Primary Analysis |
| Statistical analysis description: | |
| Cox regression, with terms for treatment, region, baseline status of diabetes, age, sex, left ventricular ejection fraction (LVEF) and glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula with serum creatinine measurement (eGFR (CKD-EPI)cr) at baseline. alpha=0.0497 (resulting from interim analysis). | |
| Comparison groups | 10 mg Empagliflozin v Placebo |

| | |
|---|----------------------------|
| Number of subjects included in analysis | 5988 |
| Analysis specification | Pre-specified |
| Analysis type | superiority ^[1] |
| P-value | = 0.0003 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.79 |
| Confidence interval | |
| level | 95.03 % |
| sides | 2-sided |
| lower limit | 0.69 |
| upper limit | 0.9 |

Notes:

[1] - H0: There is no difference between the effect of placebo and the effect of empagliflozin.

Secondary: Occurrence of adjudicated Hospitalisation for Heart Failure (HHF) (first and recurrent)

| | |
|-----------------|---|
| End point title | Occurrence of adjudicated Hospitalisation for Heart Failure (HHF) (first and recurrent) |
|-----------------|---|

End point description:

Reported is the total number of adjudicated HHF events (first and recurrent) which occurred.

Randomised Set (RS), including all randomised patients.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From randomization until completion of the planned treatment phase, up to 1403 days.

| End point values | Placebo | 10 mg Empagliflozin | | |
|-----------------------------|-----------------|------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 2991 | 2997 | | |
| Units: HHF events | 541 | 407 | | |

Statistical analyses

| | |
|----------------------------|--------------------|
| Statistical analysis title | Secondary Analysis |
|----------------------------|--------------------|

Statistical analysis description:

Joint frailty model that accounts for dependence between recurrent HHF and cardiovascular death, with terms for age, baseline eGFR (CKD-EPI)cr, baseline LVEF, region, baseline diabetes status, sex, and treatment. eGFR (CKD-EPI)cr: Glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula with serum creatinine measurement LVEF: Left ventricular ejection fraction. alpha=0.0497 (resulting from interim analysis).

| | |
|-------------------|-------------------------------|
| Comparison groups | Placebo v 10 mg Empagliflozin |
|-------------------|-------------------------------|

| | |
|---|---------------------|
| Number of subjects included in analysis | 5988 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.0009 |
| Method | Joint frailty model |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.73 |
| Confidence interval | |
| level | 95.03 % |
| sides | 2-sided |
| lower limit | 0.61 |
| upper limit | 0.88 |

Secondary: eGFR (CKD-EPI) cr slope of change from baseline

| | |
|--|---|
| End point title | eGFR (CKD-EPI) cr slope of change from baseline |
| End point description: | |
| Glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula with serum creatinine measurement (eGFR(CKD-EPI)cr) slope of change from baseline. Available on-treatment change-from-baseline data were used. Slope represents the long term effect on eGFR. Timepoints after baseline were included in calculation of slope of change from baseline. Descriptive statistic (mean(standard error)) is reported. Only patients included in the treated set (TS) and with available data for this endpoint. | |
| End point type | Secondary |
| End point timeframe: | |
| Assessed at baseline, week 4, 12, 32, 52, 76, 100, 124, 148, 172 and 196, up to 1043 days. | |

| End point values | Placebo | 10 mg Empagliflozin | | |
|--|------------------|---------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 2911 | 2925 | | |
| Units: Milliliter/minutes/ 1.73 meters squared | | | | |
| arithmetic mean (standard error) | -2.616 (± 0.108) | -1.253 (± 0.108) | | |

Statistical analyses

| | |
|--|-------------------------------|
| Statistical analysis title | Secondary Analysis |
| Statistical analysis description: | |
| Random coefficient model allowing for random intercept and random slope per patient, with factors age, baseline eGFR (CKD-EPI), baseline LVEF as linear covariate(s) and region, baseline diabetes status, sex, baseline-by-time interaction, treatment-by-time interaction and treatment as fixed effects. Only 'on-treatment' data from treated patients were used. alpha=0.001. covariance structure: Unstructured. | |
| Comparison groups | Placebo v 10 mg Empagliflozin |

| | |
|---|--------------------------------------|
| Number of subjects included in analysis | 5836 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | < 0.0001 |
| Method | Random intercept random coeff. model |
| Parameter estimate | Treatment by time interaction |
| Point estimate | 1.363 |
| Confidence interval | |
| level | Other: 99.9 % |
| sides | 2-sided |
| lower limit | 0.861 |
| upper limit | 1.865 |

Secondary: Time to the first event in the composite renal endpoint: chronic dialysis, renal transplant, or sustained reduction in eGFR (CKD-EPI)cr

| | |
|-----------------|---|
| End point title | Time to the first event in the composite renal endpoint: chronic dialysis, renal transplant, or sustained reduction in eGFR (CKD-EPI)cr |
|-----------------|---|

End point description:

Chronic dialysis was defined as dialysis with a frequency of twice per week or more for at least 90 days. Sustained was determined by two or more consecutive post-baseline central laboratory measurement separated by at least 30 days.

Reduction in glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula with serum creatinine measurement (eGFR (CKD-EPI)cr) was defined as reduction in eGFR from baseline $\geq 40\%$, eGFR < 15 mL/min/1.73 m² for patients with baseline eGFR ≥ 30 mL/min/1.73 m², or eGFR < 10 mL/min/1.73 m² for patients with baseline eGFR < 30 mL/min/1.73 m².

The incidence rate per 100 patient years ($100 \times \text{number of patients with event} / \text{time at risk [years]}$) is reported. Time at risk [year] is calculated as: Sum of time at risk [days] over all patients in a treatment group / 365.25.

Randomised Set (RS), including all randomised patients.

Abbreviation: Patient-years (pt-yrs).

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From randomization until completion of the planned treatment phase, up to 1403 days.

| End point values | Placebo | 10 mg Empagliflozin | | |
|--|---------------------|---------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 2991 | 2997 | | |
| Units: Patients with event /100 pt-yrs at risk | | | | |
| number (confidence interval 95%) | 2.23 (1.84 to 2.66) | 2.13 (1.74 to 2.54) | | |

Statistical analyses

| | |
|--|-------------------------------|
| Statistical analysis title | Secondary analysis |
| Statistical analysis description: | |
| Cox regression model included terms age, baseline glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula with serum creatinine measurement (eGFR (CKD-EPI)cr), region, baseline diabetes status, sex, baseline Left ventricular ejection fraction (LVEF) and treatment. | |
| Comparison groups | Placebo v 10 mg Empagliflozin |
| Number of subjects included in analysis | 5988 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.7243 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.95 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.73 |
| upper limit | 1.24 |

Secondary: Time to first adjudicated Hospitalisation for Heart Failure (HHF)

| | |
|-----------------|---|
| End point title | Time to first adjudicated Hospitalisation for Heart Failure (HHF) |
|-----------------|---|

End point description:

Time to first adjudicated HHF. The incidence rate per 100 patient years (pt-yrs) is presented and calculated as followed:

Incidence rate per 100 pt-yrs = $100 * \text{number of patients with event} / \text{time at risk [years]}$.

Time at risk [years] = Sum of time at risk [days] over all patients in a treatment group / 365.25.

Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier.

Randomised Set (RS), including all randomised patients.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From randomization until completion of the planned treatment phase, up to 1403 days.

| End point values | Placebo | 10 mg Empagliflozin | | |
|--|---------------------|---------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 2991 | 2997 | | |
| Units: Patients with event /100 pt-yrs at risk | | | | |
| number (confidence interval 95%) | 5.97 (5.37 to 6.62) | 4.28 (3.78 to 4.82) | | |

Statistical analyses

| | |
|--|-------------------------------|
| Statistical analysis title | Secondary Analysis |
| Statistical analysis description: | |
| Cox regression model included terms age, baseline glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula with serum creatinine measurement (eGFR (CKD-EPI)cr), region, baseline diabetes status, sex, baseline Left ventricular ejection fraction (LVEF) and treatment. | |
| Comparison groups | Placebo v 10 mg Empagliflozin |
| Number of subjects included in analysis | 5988 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | < 0.0001 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.71 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.6 |
| upper limit | 0.83 |

Secondary: Time to adjudicated cardiovascular (CV) death

| | |
|--|---|
| End point title | Time to adjudicated cardiovascular (CV) death |
| End point description: | |
| Time to adjudicated CV death. The incidence rate per 100 patient years (pt-yrs) is presented and calculated as followed: Incidence rate per 100 pt-yrs = $100 * \text{number of patients with event} / \text{time at risk [years]}$. Time at risk [years] = Sum of time at risk [days] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier. Randomised Set (RS), including all randomised patients. | |
| End point type | Secondary |
| End point timeframe: | |
| From randomization until completion of the planned treatment phase, up to 1403 days. | |

| End point values | Placebo | 10 mg Empagliflozin | | |
|---|---------------------|---------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 2991 | 2997 | | |
| Units: Patients with events /100 pt-yrs at risk | | | | |
| number (confidence interval 95%) | 3.81 (3.35 to 4.31) | 3.42 (2.98 to 3.89) | | |

Statistical analyses

| | |
|-----------------------------------|--------------------|
| Statistical analysis title | Secondary Analysis |
|-----------------------------------|--------------------|

Statistical analysis description:

Cox regression model included terms age, baseline glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula with serum creatinine measurement (eGFR (CKD-EPI)cr), region, baseline diabetes status, sex, baseline Left ventricular ejection fraction (LVEF) and treatment.

| | |
|---|-------------------------------|
| Comparison groups | Placebo v 10 mg Empagliflozin |
| Number of subjects included in analysis | 5988 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.2951 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.91 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.76 |
| upper limit | 1.09 |

Secondary: Time to all-cause mortality

| | |
|-----------------|-----------------------------|
| End point title | Time to all-cause mortality |
|-----------------|-----------------------------|

End point description:

Time to all-cause mortality. The incidence rate per 100 patient years (pt-yrs) is presented and calculated as followed:

Incidence rate per 100 pt-yrs = $100 * \text{number of patients with events} / \text{time at risk [years]}$.

Time at risk [years] = $\text{Sum of time at risk [days] over all patients in a treatment group} / 365.25$.

Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier.

Randomised Set (RS), including all randomised patients.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From randomization until completion of the planned treatment phase, up to 1403 days.

| End point values | Placebo | 10 mg Empagliflozin | | |
|---|---------------------|---------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 2991 | 2997 | | |
| Units: Patients with events /100 pt-yrs at risk | | | | |
| number (confidence interval 95%) | 6.67 (6.05 to 7.32) | 6.60 (5.98 to 7.24) | | |

Statistical analyses

| | |
|----------------------------|--------------------|
| Statistical analysis title | Secondary Analysis |
|----------------------------|--------------------|

Statistical analysis description:

Cox regression model included factors age, baseline glomerular filtration rate estimated by the chronic

kidney disease epidemiology collaboration formula with serum creatinine measurement (eGFR (CKD-EPI)cr), region, baseline diabetes status, sex, baseline Left ventricular ejection fraction (LVEF) and treatment.

| | |
|---|-------------------------------|
| Comparison groups | Placebo v 10 mg Empagliflozin |
| Number of subjects included in analysis | 5988 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.9893 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 1 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.87 |
| upper limit | 1.15 |

Secondary: Time to onset of diabetes mellitus (DM) in patients with pre-DM

| | |
|-----------------|---|
| End point title | Time to onset of diabetes mellitus (DM) in patients with pre-DM |
|-----------------|---|

End point description:

Time to onset of DM (defined as HbA1c $\geq 6.5\%$ or as diagnosed by the investigator) in patients with pre-DM.

Pre-DM was defined as no history of DM and no HbA1c $\geq 6.5\%$ before treatment, and a pre-treatment HbA1c value of $\geq 5.7\%$ and $< 6.5\%$.

The incidence rate per 100 patient years (pt-yrs) is presented and calculated as followed:

Incidence rate per 100 pt-yrs = $100 \times \text{number of patients with events} / \text{time at risk [years]}$.

Time at risk [years] = Sum of time at risk [days] over all patients in a treatment group / 365.25.

Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier.

Randomised Set (RS), including all randomised patients.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From randomization until completion of the planned treatment phase, up to 1403 days.

| End point values | Placebo | 10 mg Empagliflozin | | |
|---|---------------------|---------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 979 | 1001 | | |
| Units: Patients with events /100 pt-yrs at risk | | | | |
| number (confidence interval 95%) | 7.39 (6.21 to 8.68) | 6.12 (5.07 to 7.26) | | |

Statistical analyses

| | |
|----------------------------|--------------------|
| Statistical analysis title | Secondary Analysis |
|----------------------------|--------------------|

Statistical analysis description:

Cox regression model included factors age, baseline glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula with serum creatinine measurement (eGFR (CKD-EPI)cr), region, baseline diabetes status, sex, baseline Left ventricular ejection fraction (LVEF) and treatment.

| | |
|---|-------------------------------|
| Comparison groups | Placebo v 10 mg Empagliflozin |
| Number of subjects included in analysis | 1980 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.1539 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.84 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.65 |
| upper limit | 1.07 |

Secondary: Change from baseline in Kansas City cardiomyopathy questionnaire (KCCQ) clinical summary score at week 52

| | |
|-----------------|---|
| End point title | Change from baseline in Kansas City cardiomyopathy questionnaire (KCCQ) clinical summary score at week 52 |
|-----------------|---|

End point description:

The KCCQ is a 23-item self-administered questionnaire designed to evaluate physical limitations, symptoms (frequency, severity, and changes over time), social limitations, self-efficacy, and quality of life in patients with Heart Failure. The KCCQ-clinical summary score comprises the following domains: Symptom frequency, symptom burden and physical limitation. The score is calculated by summing domain responses and then transforming scores to a 0-100 unit scale with higher scores indicating better health status. Change from baseline in KCCQ-score at week 52 was modeled using a MMRM with visit (week 12, 32 and 52) as repeated measures, adjusted mean (standard error) at week 52 is reported. Only patients included in the treated set (TS) including values obtained on treatment.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At baseline, week 12, week 32 and week 52.

| End point values | Placebo | 10 mg Empagliflozin | | |
|-------------------------------------|-----------------|---------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 2335 | 2333 | | |
| Units: Score on a scale | | | | |
| least squares mean (standard error) | 3.18 (± 0.31) | 4.51 (± 0.31) | | |

Statistical analyses

| | |
|----------------------------|--------------------|
| Statistical analysis title | Secondary Analysis |
|----------------------------|--------------------|

Statistical analysis description:

Model includes age, baseline glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula (eGFR (CKD-EPI)), baseline Left ventricular ejection fraction (LVEF) as linear covariate(s) and region, baseline diabetes status, sex, week reachable, treatment-by-visit interaction, baseline KCCQ-Clinical-Summary-Score-by-visit interaction as fixed effect(s). Unstructured covariance structure.

| | |
|---|--------------------------------------|
| Comparison groups | Placebo v 10 mg Empagliflozin |
| Number of subjects included in analysis | 4668 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.0028 |
| Method | Mixed Model Repeated Measures (MMRM) |
| Parameter estimate | Adjusted mean difference |
| Point estimate | 1.32 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.45 |
| upper limit | 2.19 |
| Variability estimate | Standard error of the mean |
| Dispersion value | 0.44 |

Secondary: Occurrence of all-cause hospitalisation (first and recurrent)

| | |
|-----------------|---|
| End point title | Occurrence of all-cause hospitalisation (first and recurrent) |
|-----------------|---|

End point description:

Occurrence of all-cause hospitalisation (first and recurrent). Total number of all cause hospitalisations is reported.

Randomised Set (RS), including all randomised patients.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From randomization until completion of the planned treatment phase, up to 1403 days.

| End point values | Placebo | 10 mg Empagliflozin | | |
|---------------------------------------|-----------------|---------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 2991 | 2997 | | |
| Units: Hospitalisations for any cause | 2769 | 2566 | | |

Statistical analyses

| | |
|-----------------------------------|--------------------|
| Statistical analysis title | Secondary Analysis |
|-----------------------------------|--------------------|

Statistical analysis description:

Joint frailty model that accounts for the dependence between recurrent all-cause hospitalisation and all-cause mortality was used. Joint frailty model with terms for age, baseline glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula (eGFR (CKD-EPI)), baseline Left ventricular ejection fraction (LVEF), treatment, region, baseline diabetes status and sex.

| | |
|-------------------|-------------------------------|
| Comparison groups | Placebo v 10 mg Empagliflozin |
|-------------------|-------------------------------|

| | |
|---|---------------------|
| Number of subjects included in analysis | 5988 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.1012 |
| Method | Joint frailty model |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.93 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.85 |
| upper limit | 1.01 |

Adverse events

Adverse events information

Timeframe for reporting adverse events:

[All-cause Mortality]: From study start until end of study, up to 1438 days. [Serious adverse events (AE) and other AE]: From time of the first drug intake until 7 days (Residual Effect Period) after the last drug intake, up to 1410 days.

Adverse event reporting additional description:

[All-cause mortality]: Randomised Set (RS), including all randomised patients. The actual number of participants at risk for all-cause deaths is 2991 for Placebo group and 2997 for Empagliflozin group. [Serious AE and other AE]: Treated Set (TS), including all patients treated with at least one dose of the study medication.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|--------------------|--------|
| Dictionary name | MedDRA |
| Dictionary version | 23.1 |

Reporting groups

| | |
|-----------------------|---------------------|
| Reporting group title | 10 mg Empagliflozin |
|-----------------------|---------------------|

Reporting group description:

1 film-coated tablet of 10 milligram (mg) of empagliflozin was administered orally once daily in patients with chronic heart failure with preserved ejection fraction (HFpEF).

| | |
|-----------------------|---------|
| Reporting group title | Placebo |
|-----------------------|---------|

Reporting group description:

1 film-coated tablet of matching placebo was administered orally once daily in patients with chronic heart failure with preserved ejection fraction (HFpEF).

| Serious adverse events | 10 mg Empagliflozin | Placebo | |
|---|-------------------------|-------------------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1436 / 2996 (47.93%) | 1543 / 2989 (51.62%) | |
| number of deaths (all causes) | 422 | 427 | |
| number of deaths resulting from adverse events | 287 | 297 | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Acute lymphocytic leukaemia | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Adenocarcinoma | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Adenocarcinoma gastric | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Adenocarcinoma metastatic | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Adenocarcinoma of colon | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Adenocarcinoma pancreas | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Adenoid cystic carcinoma | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Adrenal gland cancer metastatic | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Angiomyolipoma | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Basal cell carcinoma | | | |
| subjects affected / exposed | 17 / 2996 (0.57%) | 32 / 2989 (1.07%) | |
| occurrences causally related to treatment / all | 0 / 19 | 0 / 37 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Benign gastric neoplasm | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Benign neoplasm of bladder | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Benign neoplasm of testis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Benign ovarian tumour | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bladder cancer | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bladder neoplasm | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bladder papilloma | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bladder transitional cell carcinoma | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bladder transitional cell carcinoma stage II | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bowen's disease | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Brain cancer metastatic | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Brain neoplasm | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Brain neoplasm malignant | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Breast cancer | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Breast cancer female | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bronchial carcinoma | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholesteatoma | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Clear cell renal cell carcinoma | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Colon adenoma | | | |
| subjects affected / exposed | 5 / 2996 (0.17%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Colon cancer | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | |
| Colon cancer metastatic | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Colon cancer stage 0 | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Colorectal cancer | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diffuse large B-cell lymphoma | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Endometrial adenocarcinoma | | | |

| | | | |
|--|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Extranodal marginal zone B-cell lymphoma (MALT type) | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastric adenoma | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastric cancer | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastric neoplasm | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Gastrointestinal adenocarcinoma | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal carcinoma | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Glomangiopericytoma | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatic cancer | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatic cancer metastatic | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatocellular carcinoma | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | |
| Intracranial tumour haemorrhage | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Intraductal proliferative breast lesion | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Invasive ductal breast carcinoma | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Invasive lobular breast carcinoma | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Invasive papillary breast carcinoma | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Keratinising squamous cell carcinoma of nasopharynx | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Laryngeal cancer | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Laryngeal squamous cell carcinoma | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Leiomyosarcoma | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lip squamous cell carcinoma | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lipoma | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lung adenocarcinoma | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 2 | |
| Lung adenocarcinoma stage IV | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Lung cancer metastatic | | | |

| | | | |
|---|-------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lung carcinoma cell type unspecified recurrent | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lung neoplasm | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Lung neoplasm malignant | | | |
| subjects affected / exposed | 10 / 2996 (0.33%) | 6 / 2989 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 10 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 4 | 0 / 1 | |
| Lung squamous cell carcinoma stage III | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lymphoma | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Malignant melanoma | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Malignant melanoma in situ | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Malignant neoplasm of renal pelvis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Malignant neoplasm of unknown primary site | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Malignant neoplasm progression | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mantle cell lymphoma | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Meningioma | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Meningioma benign | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metastases to abdominal wall | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metastases to central nervous system | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metastases to liver | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 3 / 2996 (0.10%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metastases to lung | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metastases to lymph nodes | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metastases to peritoneum | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metastatic bronchial carcinoma | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Metastatic malignant melanoma | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metastatic neoplasm | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metastatic squamous cell carcinoma | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Monoclonal gammopathy | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myelodysplastic syndrome | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Myxoid liposarcoma | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Nasal sinus cancer | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Nasopharyngeal cancer stage I | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nasopharyngeal tumour | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Neoplasm malignant | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Neuroendocrine carcinoma | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neuroendocrine carcinoma of the skin | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neuroendocrine tumour | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neuroendocrine tumour of the lung metastatic | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Non-Hodgkin's lymphoma | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Non-small cell lung cancer | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Non-small cell lung cancer metastatic | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Oesophageal cancer metastatic | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oesophageal carcinoma | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Oesophageal neoplasm | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Oesophageal squamous cell carcinoma metastatic | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ovarian neoplasm | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pancreatic carcinoma | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 1 | |
| Pancreatic carcinoma metastatic | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pancreatic neoplasm | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Papillary cystadenoma lymphomatosum | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Paraneoplastic syndrome | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Parathyroid tumour benign | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pharyngeal cancer | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pituitary tumour benign | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Plasma cell myeloma | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Prostate cancer | | | |
| subjects affected / exposed | 11 / 2996 (0.37%) | 11 / 2989 (0.37%) | |
| occurrences causally related to treatment / all | 0 / 11 | 0 / 11 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Prostate cancer metastatic | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Prostate cancer stage I | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Prostate cancer stage II | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Prostate cancer stage IV | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rectal adenocarcinoma | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rectal adenoma | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rectal cancer | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rectal neoplasm | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal adenoma | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal cancer | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal cell carcinoma | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal neoplasm | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Salivary gland cancer | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Seminoma | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Skin cancer | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Skin cancer metastatic | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Small cell lung cancer | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Small intestine carcinoma | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Squamous cell carcinoma | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Squamous cell carcinoma of lung | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 3 | |
| Squamous cell carcinoma of skin | | | |
| subjects affected / exposed | 7 / 2996 (0.23%) | 9 / 2989 (0.30%) | |
| occurrences causally related to treatment / all | 0 / 7 | 0 / 11 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Squamous cell carcinoma of the oral cavity | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Squamous cell carcinoma of the parotid gland | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| T-cell lymphoma | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thymoma | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thyroid neoplasm | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tongue neoplasm | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Tonsil cancer | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Transitional cell carcinoma | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Tumour haemorrhage | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Uterine leiomyoma | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vulval cancer | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 1 / 2 | 0 / 0 | |
| Vascular disorders | | | |
| Accelerated hypertension | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Angiodysplasia | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Aortic aneurysm | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Aortic aneurysm rupture | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 2 | |
| Aortic dissection | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 2 | |
| Aortic stenosis | | | |
| subjects affected / exposed | 7 / 2996 (0.23%) | 5 / 2989 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 7 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Aortic thrombosis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Arterial occlusive disease | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arteriosclerosis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bleeding varicose vein | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Circulatory collapse | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cyanosis | | | |

| | | | |
|---|------------------|-------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 6 / 2996 (0.20%) | 12 / 2989 (0.40%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 12 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dry gangrene | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Embolism | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Essential hypertension | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Extremity necrosis | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Femoral artery aneurysm | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haematoma | | | |
| subjects affected / exposed | 6 / 2996 (0.20%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemorrhage | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemorrhagic infarction | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypertension | | | |
| subjects affected / exposed | 8 / 2996 (0.27%) | 12 / 2989 (0.40%) | |
| occurrences causally related to treatment / all | 0 / 8 | 0 / 13 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypertensive crisis | | | |
| subjects affected / exposed | 13 / 2996 (0.43%) | 32 / 2989 (1.07%) | |
| occurrences causally related to treatment / all | 0 / 15 | 0 / 37 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Hypertensive emergency | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypertensive urgency | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 5 / 2989 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypotension | | | |
| subjects affected / exposed | 26 / 2996 (0.87%) | 19 / 2989 (0.64%) | |
| occurrences causally related to treatment / all | 6 / 28 | 2 / 20 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 0 | |
| Hypovolaemic shock | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 6 / 2989 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | |
| Iliac artery dissection | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Iliac artery occlusion | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intermittent claudication | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Malignant hypertension | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Orthostatic hypotension | | | |
| subjects affected / exposed | 6 / 2996 (0.20%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 1 / 6 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Penetrating aortic ulcer | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peripheral arterial occlusive disease | | | |
| subjects affected / exposed | 14 / 2996 (0.47%) | 16 / 2989 (0.54%) | |
| occurrences causally related to treatment / all | 0 / 14 | 0 / 19 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peripheral artery aneurysm | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peripheral artery occlusion | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 6 / 2996 (0.20%) | 6 / 2989 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 7 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peripheral artery stenosis | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peripheral artery thrombosis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peripheral embolism | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peripheral ischaemia | | | |
| subjects affected / exposed | 7 / 2996 (0.23%) | 5 / 2989 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 7 | 0 / 8 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Peripheral vascular disorder | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peripheral venous disease | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Phlebitis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Phlebitis superficial | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Shock | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Shock haemorrhagic | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | |
| Subclavian vein thrombosis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thrombophlebitis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thrombophlebitis superficial | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thrombosis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Varicose vein | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vasculitis | | | |

| | | | |
|--|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Venous thrombosis limb | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Surgical and medical procedures | | | |
| Heart valve replacement | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hospitalisation | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General disorders and administration site conditions | | | |
| Accidental death | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Asthenia | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac death | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 4 | 0 / 3 | |
| Chest discomfort | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|-------------------|-------------------|--|
| Chest pain | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 6 / 2989 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Death | | | |
| subjects affected / exposed | 56 / 2996 (1.87%) | 38 / 2989 (1.27%) | |
| occurrences causally related to treatment / all | 1 / 56 | 0 / 38 | |
| deaths causally related to treatment / all | 1 / 56 | 0 / 38 | |
| Discomfort | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Drowning | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Fatigue | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Fibrosis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gait disturbance | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General physical health deterioration | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hernia | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyperthermia | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypothermia | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Impaired healing | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Inflammation | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Injection site phlebitis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Malaise | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Multiple organ dysfunction syndrome | | | |
| subjects affected / exposed | 6 / 2996 (0.20%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 2 | |
| Medical device site oedema | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Necrosis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 14 / 2996 (0.47%) | 16 / 2989 (0.54%) | |
| occurrences causally related to treatment / all | 0 / 14 | 0 / 16 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Physical deconditioning | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pacemaker generated arrhythmia | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pyrexia | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Stent-graft endoleak | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Strangulated hernia | | | |

| | | | |
|---|-------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sudden cardiac death | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 9 / 2989 (0.30%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 9 | |
| deaths causally related to treatment / all | 0 / 4 | 0 / 9 | |
| Sudden death | | | |
| subjects affected / exposed | 10 / 2996 (0.33%) | 8 / 2989 (0.27%) | |
| occurrences causally related to treatment / all | 0 / 10 | 0 / 8 | |
| deaths causally related to treatment / all | 0 / 10 | 0 / 8 | |
| Systemic inflammatory response syndrome | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular stent stenosis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular stent occlusion | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Vessel puncture site bruise | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Immune system disorders | | | |
| Allergy to vaccine | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Amyloidosis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Anaphylactic reaction | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Corneal graft rejection | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Reproductive system and breast disorders | | | |
| Acquired hydrocele | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Acquired phimosis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Benign prostatic hyperplasia | | | |
| subjects affected / exposed | 8 / 2996 (0.27%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 8 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Adnexa uteri mass | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cervix disorder | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Postmenopausal haemorrhage | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Prostatitis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Uterine inflammation | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Uterine polyp | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Uterine prolapse | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vaginal haemorrhage | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Acute respiratory distress syndrome | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Acute pulmonary oedema | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 7 / 2989 (0.23%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 7 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | |
| Aspiration | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Acute respiratory failure | | | |
| subjects affected / exposed | 8 / 2996 (0.27%) | 20 / 2989 (0.67%) | |
| occurrences causally related to treatment / all | 0 / 8 | 0 / 24 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 3 | |
| Bronchitis chronic | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Asthma | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bronchospasm | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Choking | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Chronic obstructive pulmonary disease | | | |
| subjects affected / exposed | 23 / 2996 (0.77%) | 37 / 2989 (1.24%) | |
| occurrences causally related to treatment / all | 0 / 30 | 0 / 44 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 3 | |
| Combined pulmonary fibrosis and emphysema | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cough | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dyspnoea | | | |
| subjects affected / exposed | 9 / 2996 (0.30%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 9 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Emphysema | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Epistaxis | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 5 / 2989 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemoptysis | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemothorax | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hydrothorax | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypersensitivity pneumonitis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyperventilation | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypoventilation | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypoxia | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Idiopathic pulmonary fibrosis | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Interstitial lung disease | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 0 | |
| Nasal polyps | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Obstructive airways disorder | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pleural effusion | | | |
| subjects affected / exposed | 8 / 2996 (0.27%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 11 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pleural thickening | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pleurisy | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 5 / 2989 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumothorax | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumothorax spontaneous | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pulmonary arterial hypertension | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pulmonary congestion | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 5 / 2989 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pulmonary embolism | | | |

| | | | |
|---|------------------|-------------------|--|
| subjects affected / exposed | 5 / 2996 (0.17%) | 11 / 2989 (0.37%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 12 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Pulmonary fibrosis | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Pulmonary hypertension | | | |
| subjects affected / exposed | 8 / 2996 (0.27%) | 13 / 2989 (0.43%) | |
| occurrences causally related to treatment / all | 0 / 8 | 0 / 13 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pulmonary mass | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pulmonary oedema | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 6 / 2989 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Respiratory arrest | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory disorder | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Respiratory distress | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Respiratory failure | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 14 / 2996 (0.47%) | 15 / 2989 (0.50%) | |
| occurrences causally related to treatment / all | 0 / 14 | 0 / 15 | |
| deaths causally related to treatment / all | 0 / 3 | 0 / 1 | |
| Restrictive pulmonary disease | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sinus polyp | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sleep apnoea syndrome | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Psychiatric disorders | | | |
| Adjustment disorder | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Anxiety | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Anxiety disorder | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bipolar I disorder | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bipolar disorder | | | |

| | | | |
|---|------------------|-------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Completed suicide | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 3 | |
| Confusional state | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Delirium | | | |
| subjects affected / exposed | 9 / 2996 (0.30%) | 12 / 2989 (0.40%) | |
| occurrences causally related to treatment / all | 0 / 10 | 0 / 12 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Depression | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Disorientation | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Insomnia | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nosophobia | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Paranoia | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Post-traumatic stress disorder | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Suicide attempt | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Product issues | | | |
| Device breakage | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Device dislocation | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Device failure | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Device leakage | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Device malfunction | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thrombosis in device | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatobiliary disorders | | | |
| Bile duct stone | | | |
| subjects affected / exposed | 6 / 2996 (0.20%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Biliary colic | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Biliary obstruction | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac cirrhosis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholangitis | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 2 | |
| Cholangitis acute | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholecystitis | | | |
| subjects affected / exposed | 6 / 2996 (0.20%) | 6 / 2989 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholecystitis acute | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 4 / 2996 (0.13%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholecystitis chronic | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholelithiasis | | | |
| subjects affected / exposed | 6 / 2996 (0.20%) | 7 / 2989 (0.23%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 7 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholestasis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholestatic liver injury | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Drug-induced liver injury | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatic cirrhosis | | | |
| subjects affected / exposed | 7 / 2996 (0.23%) | 6 / 2989 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 7 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatic failure | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatic function abnormal | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 3 / 2996 (0.10%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 1 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatitis acute | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatitis cholestatic | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatorenal failure | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Hepatorenal syndrome | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ischaemic hepatitis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Jaundice | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Jaundice cholestatic | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Liver disorder | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 2 / 2996 (0.07%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Liver injury | | | |
| subjects affected / exposed | 7 / 2996 (0.23%) | 9 / 2989 (0.30%) | |
| occurrences causally related to treatment / all | 0 / 7 | 1 / 9 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Investigations | | | |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Anticoagulation drug level above therapeutic | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 6 / 2989 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Anticoagulation drug level below therapeutic | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood creatine phosphokinase increased | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood creatinine increased | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|------------------|------------------|--|
| Blood ketone body increased subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood potassium increased subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood pressure increased subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood urine present subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Brain natriuretic peptide subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| C-reactive protein increased subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ejection fraction decreased subjects affected / exposed | 0 / 2996 (0.00%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Glomerular filtration rate decreased subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatic enzyme increased | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Liver function test abnormal | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Occult blood positive | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Prostatic specific antigen abnormal | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Transaminases increased | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Troponin increased | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Weight decreased | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Injury, poisoning and procedural complications | | | |
| Accidental overdose | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Alcohol poisoning | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ankle fracture | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Animal bite | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Back injury | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Brain contusion | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Burns second degree | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Burns third degree | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bursa injury | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chest injury | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cervical vertebral fracture | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Clavicle fracture | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Concussion | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Contusion | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Corneal graft failure | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Coronary artery restenosis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Craniocerebral injury | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Craniofacial fracture | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cystitis radiation | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diffuse axonal injury | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Deafness traumatic | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dural tear | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dislocation of vertebra | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Epidural haemorrhage | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Facial bones fracture | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Fall | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 31 / 2996 (1.03%) | 30 / 2989 (1.00%) | |
| occurrences causally related to treatment / all | 1 / 34 | 0 / 32 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Femoral neck fracture | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Femur fracture | | | |
| subjects affected / exposed | 14 / 2996 (0.47%) | 12 / 2989 (0.40%) | |
| occurrences causally related to treatment / all | 0 / 14 | 0 / 12 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Fibula fracture | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Forearm fracture | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal injury | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Genital contusion | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hand fracture | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Head injury | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 3 / 2996 (0.10%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Heart injury | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Heat stroke | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hip fracture | | | |
| subjects affected / exposed | 9 / 2996 (0.30%) | 7 / 2989 (0.23%) | |
| occurrences causally related to treatment / all | 0 / 9 | 0 / 7 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Humerus fracture | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 5 / 2989 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Incision site haemorrhage | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Incisional hernia | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intentional overdose | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Jaw fracture | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Joint dislocation postoperative | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Joint injury | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Limb injury | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Limb traumatic amputation | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lower limb fracture | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lumbar vertebral fracture | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Maisonneuve fracture | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Meniscus injury | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Multiple fractures | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Muscle injury | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Overdose | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Patella fracture | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pelvic fracture | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 7 / 2989 (0.23%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 7 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Periprocedural myocardial infarction | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Periprosthetic fracture | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Post procedural complication | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Post procedural haemorrhage | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Post procedural hypotension | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Post procedural inflammation | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Postoperative ileus | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Postoperative delirium | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Postoperative renal failure | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Procedural complication | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Procedural pain | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pulmonary contusion | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Procedural shock | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Radius fracture | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rib fracture | | | |
| subjects affected / exposed | 6 / 2996 (0.20%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Road traffic accident | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 0 | |
| Scapula fracture | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Skin injury | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Skin laceration | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Skull fractured base | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Spinal compression fracture | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sternal fracture | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Spinal fracture | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Subdural haematoma | | | |
| subjects affected / exposed | 8 / 2996 (0.27%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 1 / 8 | 0 / 4 | |
| deaths causally related to treatment / all | 1 / 1 | 0 / 1 | |
| Subcutaneous haematoma | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Subdural haemorrhage | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Tendon rupture | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thoracic vertebral fracture | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Toxicity to various agents | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tibia fracture | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Traumatic fracture | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Traumatic haemorrhage | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Traumatic haemothorax | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Traumatic spinal cord compression | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Upper limb fracture | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urethral injury | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urethral stricture postoperative | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular pseudoaneurysm | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Wrist fracture | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Congenital, familial and genetic disorders | | | |
| Atrial septal defect | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Buried penis syndrome | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Congenital cystic kidney disease | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypertrophic cardiomyopathy | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Phimosis | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pyloric stenosis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Talipes | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Type V hyperlipidaemia | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac disorders | | | |
| Acute coronary syndrome | | | |
| subjects affected / exposed | 8 / 2996 (0.27%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 8 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Acute left ventricular failure | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Acute myocardial infarction | | | |
| subjects affected / exposed | 50 / 2996 (1.67%) | 48 / 2989 (1.61%) | |
| occurrences causally related to treatment / all | 0 / 55 | 0 / 50 | |
| deaths causally related to treatment / all | 0 / 7 | 0 / 8 | |
| Adams-Stokes syndrome | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Angina pectoris | | | |
| subjects affected / exposed | 28 / 2996 (0.93%) | 23 / 2989 (0.77%) | |
| occurrences causally related to treatment / all | 0 / 28 | 0 / 24 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Angina unstable | | | |
| subjects affected / exposed | 26 / 2996 (0.87%) | 23 / 2989 (0.77%) | |
| occurrences causally related to treatment / all | 0 / 28 | 1 / 28 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Aortic valve incompetence | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Aortic valve stenosis | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arrhythmia | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 5 / 2989 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arrhythmia supraventricular | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atrial fibrillation | | | |
| subjects affected / exposed | 92 / 2996 (3.07%) | 80 / 2989 (2.68%) | |
| occurrences causally related to treatment / all | 1 / 117 | 0 / 94 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 0 | |
| Atrial flutter | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 14 / 2996 (0.47%) | 21 / 2989 (0.70%) | |
| occurrences causally related to treatment / all | 0 / 17 | 0 / 22 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atrial tachycardia | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atrial thrombosis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atrioventricular block | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atrioventricular block complete | | | |
| subjects affected / exposed | 11 / 2996 (0.37%) | 5 / 2989 (0.17%) | |
| occurrences causally related to treatment / all | 2 / 11 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atrioventricular block second degree | | | |
| subjects affected / exposed | 6 / 2996 (0.20%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bradyarrhythmia | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Bradycardia | | | |
| subjects affected / exposed | 6 / 2996 (0.20%) | 6 / 2989 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bundle branch block left | | | |

| | | | |
|---|---------------------|---------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bundle branch block right | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac amyloidosis | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac arrest | | | |
| subjects affected / exposed | 12 / 2996 (0.40%) | 8 / 2989 (0.27%) | |
| occurrences causally related to treatment / all | 0 / 12 | 0 / 9 | |
| deaths causally related to treatment / all | 0 / 7 | 0 / 6 | |
| Cardiac failure | | | |
| subjects affected / exposed | 448 / 2996 (14.95%) | 594 / 2989 (19.87%) | |
| occurrences causally related to treatment / all | 18 / 669 | 15 / 901 | |
| deaths causally related to treatment / all | 0 / 35 | 1 / 52 | |
| Cardiac failure acute | | | |
| subjects affected / exposed | 12 / 2996 (0.40%) | 29 / 2989 (0.97%) | |
| occurrences causally related to treatment / all | 0 / 16 | 0 / 33 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 5 | |
| Cardiac failure chronic | | | |
| subjects affected / exposed | 25 / 2996 (0.83%) | 30 / 2989 (1.00%) | |
| occurrences causally related to treatment / all | 0 / 29 | 1 / 48 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 2 | |
| Cardiac failure congestive | | | |
| subjects affected / exposed | 57 / 2996 (1.90%) | 66 / 2989 (2.21%) | |
| occurrences causally related to treatment / all | 1 / 73 | 0 / 100 | |
| deaths causally related to treatment / all | 0 / 3 | 0 / 4 | |
| Cardiac sarcoidosis | | | |

| | | | |
|---|------------------|-------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac ventricular thrombosis | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardio-respiratory arrest | | | |
| subjects affected / exposed | 5 / 2996 (0.17%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 3 | 0 / 0 | |
| Cardiogenic shock | | | |
| subjects affected / exposed | 5 / 2996 (0.17%) | 12 / 2989 (0.40%) | |
| occurrences causally related to treatment / all | 1 / 5 | 0 / 12 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 6 | |
| Cardiopulmonary failure | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 2 | |
| Cardiorenal syndrome | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiovascular disorder | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chronic left ventricular failure | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chronotropic incompetence | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Coronary artery disease | | | |
| subjects affected / exposed | 22 / 2996 (0.73%) | 32 / 2989 (1.07%) | |
| occurrences causally related to treatment / all | 0 / 24 | 0 / 34 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Coronary artery insufficiency | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Coronary artery occlusion | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Coronary artery stenosis | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 8 / 2989 (0.27%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 8 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Left ventricular dysfunction | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ischaemic cardiomyopathy | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Left ventricular hypertrophy | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Left ventricular failure | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mitral valve disease | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mitral valve incompetence | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 7 / 2989 (0.23%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 7 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mitral valve stenosis | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myocardial infarction | | | |
| subjects affected / exposed | 37 / 2996 (1.23%) | 27 / 2989 (0.90%) | |
| occurrences causally related to treatment / all | 1 / 39 | 0 / 28 | |
| deaths causally related to treatment / all | 0 / 8 | 0 / 12 | |
| Myocardial ischaemia | | | |
| subjects affected / exposed | 8 / 2996 (0.27%) | 9 / 2989 (0.30%) | |
| occurrences causally related to treatment / all | 0 / 9 | 0 / 9 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Myocardial necrosis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myocarditis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Palpitations | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pericardial effusion | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Prinzmetal angina | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pulseless electrical activity | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Right ventricular failure | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sinoatrial block | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Silent myocardial infarction | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sinus arrest | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sinus bradycardia | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 7 / 2996 (0.23%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 7 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sinus node dysfunction | | | |
| subjects affected / exposed | 8 / 2996 (0.27%) | 8 / 2989 (0.27%) | |
| occurrences causally related to treatment / all | 0 / 9 | 0 / 8 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Stress cardiomyopathy | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Supraventricular tachyarrhythmia | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Supraventricular tachycardia | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tachyarrhythmia | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Torsade de pointes | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tricuspid valve incompetence | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ventricular arrhythmia | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ventricular dyskinesia | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ventricular extrasystoles | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ventricular failure | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ventricular fibrillation | | | |
| subjects affected / exposed | 5 / 2996 (0.17%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ventricular tachycardia | | | |
| subjects affected / exposed | 22 / 2996 (0.73%) | 22 / 2989 (0.74%) | |
| occurrences causally related to treatment / all | 1 / 24 | 0 / 25 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Nervous system disorders | | | |
| Altered state of consciousness | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 1 / 1 | |
| Arachnoid cyst | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Brain compression | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Brain injury | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Brain oedema | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Brain stem ischaemia | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Brain stem stroke | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Carotid arteriosclerosis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Carotid artery aneurysm | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Carotid artery disease | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Carotid artery dissection | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Carotid artery occlusion | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Carotid artery stenosis | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Carpal tunnel syndrome | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Central nervous system lesion | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebellar haematoma | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebellar infarction | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebral arteriosclerosis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebral artery embolism | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Cerebral artery occlusion | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebral atrophy | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebral disorder | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebral haematoma | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Cerebral haemorrhage | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 0 | |
| Cerebral infarction | | | |
| subjects affected / exposed | 14 / 2996 (0.47%) | 10 / 2989 (0.33%) | |
| occurrences causally related to treatment / all | 1 / 14 | 0 / 10 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Cerebral ischaemia | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Cerebral small vessel ischaemic disease | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebrospinal fluid leakage | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 21 / 2996 (0.70%) | 20 / 2989 (0.67%) | |
| occurrences causally related to treatment / all | 0 / 21 | 0 / 21 | |
| deaths causally related to treatment / all | 0 / 6 | 0 / 1 | |
| Cervical cord compression | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cervical radiculopathy | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chronic inflammatory demyelinating polyradiculoneuropathy | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cognitive disorder | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Coma | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cranial nerve palsies multiple | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dementia | | | |
| subjects affected / exposed | 14 / 2996 (0.47%) | 10 / 2989 (0.33%) | |
| occurrences causally related to treatment / all | 1 / 14 | 0 / 10 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dementia Alzheimer's type | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Demyelination | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Disturbance in attention | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dizziness | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 6 / 2989 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 3 | 1 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Drop attacks | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dysarthria | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Embolic cerebral infarction | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Embolic stroke | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Encephalomalacia | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Encephalopathy | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Epilepsy | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Generalised tonic-clonic seizure | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemorrhage intracranial | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Haemorrhagic stroke | | | |
| subjects affected / exposed | 7 / 2996 (0.23%) | 7 / 2989 (0.23%) | |
| occurrences causally related to treatment / all | 0 / 7 | 1 / 7 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 3 | |
| Haemorrhagic transformation stroke | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Headache | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hemiparesis | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hemiplegia | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatic encephalopathy | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hydrocephalus | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypertensive encephalopathy | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypoaesthesia | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypoglycaemic seizure | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypoxic-ischaemic encephalopathy | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Intracranial aneurysm | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ischaemic cerebral infarction | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ischaemic stroke | | | |
| subjects affected / exposed | 42 / 2996 (1.40%) | 35 / 2989 (1.17%) | |
| occurrences causally related to treatment / all | 1 / 46 | 0 / 36 | |
| deaths causally related to treatment / all | 0 / 10 | 0 / 6 | |
| Lacunar infarction | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lacunar stroke | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Loss of consciousness | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 2 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lumbar radiculopathy | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Migraine | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nervous system disorder | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Neurological symptom | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Paraesthesia | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Paraplegia | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Parkinson's disease | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Parkinsonism | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Posterior cortical atrophy | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Postresuscitation encephalopathy | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Presyncope | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sciatica | | | |
| subjects affected / exposed | 5 / 2996 (0.17%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Seizure | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 7 / 2989 (0.23%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 7 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Senile dementia | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sensorimotor disorder | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Speech disorder | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Status epilepticus | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Subarachnoid haemorrhage | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 5 / 2989 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Syncope | | | |
| subjects affected / exposed | 23 / 2996 (0.77%) | 19 / 2989 (0.64%) | |
| occurrences causally related to treatment / all | 1 / 23 | 2 / 20 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | |
| Thalamus haemorrhage | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Thoracic radiculopathy | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Toxic encephalopathy | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Transient global amnesia | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Transient ischaemic attack | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 20 / 2996 (0.67%) | 21 / 2989 (0.70%) | |
| occurrences causally related to treatment / all | 0 / 21 | 1 / 21 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tremor | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular dementia | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Vascular encephalopathy | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vertebral artery stenosis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vertebral artery thrombosis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vertebrobasilar insufficiency | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 19 / 2996 (0.63%) | 30 / 2989 (1.00%) | |
| occurrences causally related to treatment / all | 0 / 24 | 0 / 34 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Anaemia macrocytic | | | |

| | | | |
|---|------------------|-------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Anaemia megaloblastic | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood loss anaemia | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Coagulopathy | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Disseminated intravascular coagulation | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypochromic anaemia | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Immune thrombocytopenia | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 6 / 2996 (0.20%) | 12 / 2989 (0.40%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 14 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Leukocytosis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lymphadenopathy mediastinal | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Microcytic anaemia | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Normocytic anaemia | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pancytopenia | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Splenic infarction | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thrombocytopenia | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Ear and labyrinth disorders | | | |
| Deafness | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Deafness bilateral | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Deafness neurosensory | | | |
| subjects affected / exposed | 5 / 2996 (0.17%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Deafness unilateral | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypoacusis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mixed deafness | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sudden hearing loss | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tinnitus | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vertigo | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vertigo positional | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 4 / 2996 (0.13%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vestibular disorder | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Eye disorders | | | |
| Amaurosis fugax | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blindness transient | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cataract | | | |
| subjects affected / exposed | 10 / 2996 (0.33%) | 10 / 2989 (0.33%) | |
| occurrences causally related to treatment / all | 0 / 10 | 0 / 11 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cataract nuclear | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetic retinopathy | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Conjunctival disorder | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Glaucoma | | | |

| | | | |
|---|------------------|-------------------|--|
| subjects affected / exposed | 8 / 2996 (0.27%) | 10 / 2989 (0.33%) | |
| occurrences causally related to treatment / all | 1 / 8 | 0 / 11 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Eyelid ptosis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Macular fibrosis | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Macular degeneration | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Macular hole | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Macular ischaemia | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neovascular age-related macular degeneration | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Normal tension glaucoma | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Open angle glaucoma | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 2 / 2996 (0.07%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Optic ischaemic neuropathy | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Retinal artery embolism | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Retinal artery occlusion | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Retinal detachment | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Retinal ischaemia | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Retinal tear | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Visual acuity reduced | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Retinal vein occlusion | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 2 / 2996 (0.07%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vitreous haemorrhage | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| Abdominal hernia | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Abdominal mass | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Abdominal pain | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Abdominal pain lower | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Acute abdomen | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ascites | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 4 / 2996 (0.13%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 8 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Barrett's oesophagus | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chronic gastritis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chronic gastrointestinal bleeding | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Colitis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Colitis ischaemic | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Colitis ulcerative | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Constipation | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diaphragmatic hernia | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diarrhoea | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diverticular perforation | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Diverticulum | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diverticulum intestinal | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diverticulum intestinal haemorrhagic | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Duodenal ulcer haemorrhage | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Duodenitis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dyspepsia | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dysphagia | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Enteritis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Enterocolitis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Enterovesical fistula | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Faecal vomiting | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastric haemorrhage | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastric polyps | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastric ulcer | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 2 / 2996 (0.07%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastric ulcer haemorrhage | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastric ulcer perforation | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastritis | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 6 / 2989 (0.20%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastritis erosive | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 14 / 2996 (0.47%) | 17 / 2989 (0.57%) | |
| occurrences causally related to treatment / all | 0 / 15 | 0 / 18 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal inflammation | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal necrosis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal perforation | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal obstruction | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal polyp | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal ulcer | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haematochezia | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemorrhagic ascites | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemorrhoidal haemorrhage | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hiatus hernia | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemorrhoids | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ileus paralytic | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ileus | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Incarcerated umbilical hernia | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Incarcerated inguinal hernia | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Inguinal hernia | | | |
| subjects affected / exposed | 8 / 2996 (0.27%) | 9 / 2989 (0.30%) | |
| occurrences causally related to treatment / all | 0 / 8 | 0 / 9 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intestinal angina | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intestinal haemorrhage | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intestinal infarction | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Intestinal ischaemia | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Intestinal obstruction | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Intestinal perforation | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intestinal polyp | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intestinal pseudo-obstruction | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intestinal strangulation | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intra-abdominal haemorrhage | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Large intestinal haemorrhage | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Large intestinal stenosis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Large intestinal ulcer | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Large intestine perforation | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Large intestine polyp | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lower gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Mechanical ileus | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Melaena | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mesenteric artery embolism | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mesenteric artery stenosis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mesenteric artery thrombosis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nausea | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Obstructive pancreatitis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oesophageal achalasia | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oesophageal haemorrhage | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Oesophageal rupture | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oesophageal spasm | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oesophageal varices haemorrhage | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oesophagitis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pancreatic disorder | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pancreatic failure | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pancreatitis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pancreatitis acute | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Pancreatitis chronic | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peptic ulcer | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumoperitoneum | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rectal prolapse | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rectal ulcer | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Retroperitoneal fibrosis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Retroperitoneal haemorrhage | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Salivary gland calculus | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Small intestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Small intestinal obstruction | | | |
| subjects affected / exposed | 5 / 2996 (0.17%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Small intestinal perforation | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Small intestinal stenosis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Stomach mass | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Subacute pancreatitis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Subileus | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thrombosis mesenteric vessel | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Umbilical hernia | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Upper gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 5 / 2996 (0.17%) | 7 / 2989 (0.23%) | |
| occurrences causally related to treatment / all | 0 / 5 | 1 / 8 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Volvulus | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vomiting | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 1 / 2 | 1 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Skin and subcutaneous tissue disorders | | | |
| Actinic keratosis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Angioedema | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetic foot | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 5 / 2989 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetic ulcer | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Paraneoplastic dermatomyositis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peau d'orange | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pemphigoid | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Psoriasis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pyoderma gangrenosum | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rash erythematous | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Skin necrosis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Skin ulcer | | | |

| | | | |
|---|-------------------|--------------------|--|
| subjects affected / exposed | 6 / 2996 (0.20%) | 11 / 2989 (0.37%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 11 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Stasis dermatitis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 81 / 2996 (2.70%) | 107 / 2989 (3.58%) | |
| occurrences causally related to treatment / all | 14 / 98 | 16 / 122 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 2 | |
| Bladder tamponade | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Calculus urinary | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chronic kidney disease | | | |
| subjects affected / exposed | 16 / 2996 (0.53%) | 25 / 2989 (0.84%) | |
| occurrences causally related to treatment / all | 1 / 16 | 6 / 27 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Cystitis haemorrhagic | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetic nephropathy | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| End stage renal disease | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haematuria | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hydronephrosis | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ketonuria | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nephrolithiasis | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nephropathy | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nephropathy toxic | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nephrotic syndrome | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neurogenic bladder | | | |

| | | | |
|---|------------------|-------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pelvi-ureteric obstruction | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pollakiuria | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Postrenal failure | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Proteinuria | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal artery stenosis | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal colic | | | |
| subjects affected / exposed | 5 / 2996 (0.17%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 5 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal failure | | | |
| subjects affected / exposed | 9 / 2996 (0.30%) | 21 / 2989 (0.70%) | |
| occurrences causally related to treatment / all | 0 / 9 | 2 / 21 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Renal impairment | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 38 / 2996 (1.27%) | 42 / 2989 (1.41%) | |
| occurrences causally related to treatment / all | 7 / 41 | 9 / 42 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 1 | |
| Renal injury | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal tubular necrosis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ureterolithiasis | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urethral cyst | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urethral caruncle | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urethral stenosis | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary bladder rupture | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary incontinence | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary retention | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 5 / 2989 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vesical fistula | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary tract obstruction | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Endocrine disorders | | | |
| Adrenal insufficiency | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Basedow's disease | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Goitre | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyperplasia adrenal | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyperthyroidism | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 2 / 2996 (0.07%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Secondary adrenocortical insufficiency | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pituitary apoplexy | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| Acquired claw toe | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arthralgia | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arthritis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arthropathy | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Back pain | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 8 / 2989 (0.27%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 9 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bursitis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Compartment syndrome | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Costochondritis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dupuytren's contracture | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Exostosis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Fistula | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Flank pain | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gouty arthritis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Groin pain | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemarthrosis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haematoma muscle | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intervertebral disc degeneration | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intervertebral disc protrusion | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 5 / 2989 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Joint range of motion decreased | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lumbar spinal stenosis | | | |
| subjects affected / exposed | 5 / 2996 (0.17%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Muscle spasms | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Muscle twitching | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Muscular weakness | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myopathy | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myositis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neck pain | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Osteitis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Osteoarthritis | | | |
| subjects affected / exposed | 11 / 2996 (0.37%) | 16 / 2989 (0.54%) | |
| occurrences causally related to treatment / all | 0 / 12 | 0 / 17 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Osteonecrosis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 3 / 2996 (0.10%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Osteoporosis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pain in extremity | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pathological fracture | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Polymyalgia rheumatica | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 9 / 2989 (0.30%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 9 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rhabdomyolysis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 5 / 2989 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rotator cuff syndrome | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sacroiliac joint dysfunction | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sarcopenia | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Scleroderma | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sjogren's syndrome | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Soft tissue necrosis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Spinal osteoarthritis | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Spinal pain | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Spinal stenosis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Synovitis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tendonitis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vertebral column mass | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Abdominal infection | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Abdominal sepsis | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | |
| Abscess | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Abscess limb | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Abscess neck | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Acinetobacter infection | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Acute sinusitis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Anal abscess | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Appendicitis | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 5 / 2989 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Arthritis bacterial | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atypical pneumonia | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bacteraemia | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bacterial food poisoning | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bacterial sepsis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bacterial translocation | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Breast cellulitis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Breast abscess | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bronchitis | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 12 / 2989 (0.40%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 14 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | |
| Bronchitis bacterial | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bullous erysipelas | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bursitis infective | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| COVID-19 | | | |
| subjects affected / exposed | 49 / 2996 (1.64%) | 47 / 2989 (1.57%) | |
| occurrences causally related to treatment / all | 0 / 49 | 0 / 47 | |
| deaths causally related to treatment / all | 0 / 12 | 0 / 9 | |
| COVID-19 pneumonia | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 25 / 2996 (0.83%) | 17 / 2989 (0.57%) | |
| occurrences causally related to treatment / all | 0 / 25 | 0 / 18 | |
| deaths causally related to treatment / all | 0 / 10 | 0 / 6 | |
| Cardiac valve abscess | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholangitis infective | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Cellulitis | | | |
| subjects affected / exposed | 22 / 2996 (0.73%) | 8 / 2989 (0.27%) | |
| occurrences causally related to treatment / all | 0 / 23 | 0 / 8 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholecystitis infective | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chronic sinusitis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Clostridial sepsis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Clostridium difficile colitis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 5 / 2989 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Clostridium difficile infection | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Colon gangrene | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Complicated appendicitis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Coronavirus infection | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Cystitis | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 2 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dengue fever | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Device related infection | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Device related sepsis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetic foot infection | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetic gangrene | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diverticulitis | | | |
| subjects affected / exposed | 6 / 2996 (0.20%) | 5 / 2989 (0.17%) | |
| occurrences causally related to treatment / all | 1 / 6 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dysentery | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Endocarditis | | | |
| subjects affected / exposed | 5 / 2996 (0.17%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Endocarditis bacterial | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Endocarditis staphylococcal | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Enteritis infectious | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Enterobacter sepsis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Enterococcal bacteraemia | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Epididymitis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Erysipelas | | | |
| subjects affected / exposed | 5 / 2996 (0.17%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Escherichia sepsis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Fournier's gangrene | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 2 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Fungal oesophagitis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gallbladder empyema | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gangrene | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 4 / 2996 (0.13%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Gastroenteritis | | | |
| subjects affected / exposed | 8 / 2996 (0.27%) | 7 / 2989 (0.23%) | |
| occurrences causally related to treatment / all | 0 / 10 | 0 / 7 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastroenteritis norovirus | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastroenteritis rotavirus | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastroenteritis viral | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal infection | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haematoma infection | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Helicobacter gastritis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Helicobacter infection | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatitis A | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Herpes zoster | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Herpes zoster infection neurological | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infected dermal cyst | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infected gouty tophus | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infected skin ulcer | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infection | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infectious pleural effusion | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infective exacerbation of chronic obstructive airways disease | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Influenza | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 5 / 2989 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intervertebral discitis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intestinal sepsis | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Joint abscess | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Klebsiella infection | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Klebsiella bacteraemia | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Labyrinthitis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Large intestine infection | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Liver abscess | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Localised infection | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lower respiratory tract infection | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ludwig angina | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lung abscess | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Mastoiditis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Meningitis bacterial | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neurocysticercosis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Orchitis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Osteomyelitis | | | |
| subjects affected / exposed | 6 / 2996 (0.20%) | 5 / 2989 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Osteomyelitis acute | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pathogen resistance | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Parotid abscess | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Perineal abscess | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Periodontitis | | | |

| | | | |
|---|--------------------|--------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peritonitis | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Peritonitis bacterial | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peritonsillar abscess | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peritonsillitis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Petrositis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia | | | |
| subjects affected / exposed | 100 / 2996 (3.34%) | 119 / 2989 (3.98%) | |
| occurrences causally related to treatment / all | 0 / 108 | 2 / 130 | |
| deaths causally related to treatment / all | 0 / 9 | 0 / 11 | |
| Pneumonia bacterial | | | |
| subjects affected / exposed | 6 / 2996 (0.20%) | 8 / 2989 (0.27%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 8 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia parainfluenzae viral | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia pneumococcal | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia viral | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Postoperative abscess | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Postoperative wound infection | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Prostatitis Escherichia coli | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pseudomembranous colitis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pulmonary sepsis | | | |
| subjects affected / exposed | 5 / 2996 (0.17%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | |
| Pulmonary tuberculosis | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pyelonephritis | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 1 / 3 | 2 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pyelonephritis acute | | | |
| subjects affected / exposed | 7 / 2996 (0.23%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 4 / 7 | 1 / 3 | |
| deaths causally related to treatment / all | 1 / 1 | 0 / 0 | |
| Respiratory tract infection | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sepsis | | | |
| subjects affected / exposed | 26 / 2996 (0.87%) | 21 / 2989 (0.70%) | |
| occurrences causally related to treatment / all | 1 / 26 | 0 / 21 | |
| deaths causally related to treatment / all | 0 / 7 | 0 / 10 | |
| Septic shock | | | |
| subjects affected / exposed | 11 / 2996 (0.37%) | 11 / 2989 (0.37%) | |
| occurrences causally related to treatment / all | 0 / 11 | 0 / 11 | |
| deaths causally related to treatment / all | 0 / 5 | 0 / 6 | |
| Severe acute respiratory syndrome | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 2 | |
| Severe fever with thrombocytopenia syndrome | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Small intestine gangrene | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Soft tissue infection | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Staphylococcal bacteraemia | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Staphylococcal sepsis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Staphylococcal skin infection | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Streptococcal bacteraemia | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Streptococcal infection | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Streptococcal sepsis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Superinfection | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Suspected COVID-19 | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Systemic bacterial infection | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Systemic candida | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Testicular abscess | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tooth abscess | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tracheobronchitis | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary tract infection | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 36 / 2996 (1.20%) | 28 / 2989 (0.94%) | |
| occurrences causally related to treatment / all | 16 / 37 | 9 / 31 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urosepsis | | | |
| subjects affected / exposed | 12 / 2996 (0.40%) | 12 / 2989 (0.40%) | |
| occurrences causally related to treatment / all | 4 / 12 | 7 / 12 | |
| deaths causally related to treatment / all | 0 / 1 | 1 / 3 | |
| Viral upper respiratory tract infection | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Wound abscess | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Wound infection | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Wound infection staphylococcal | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Wound sepsis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metabolism and nutrition disorders | | | |
| Cachexia | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 3 | 0 / 0 | |
| Decreased appetite | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dehydration | | | |
| subjects affected / exposed | 8 / 2996 (0.27%) | 8 / 2989 (0.27%) | |
| occurrences causally related to treatment / all | 2 / 8 | 0 / 8 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Diabetes mellitus | | | |
| subjects affected / exposed | 5 / 2996 (0.17%) | 15 / 2989 (0.50%) | |
| occurrences causally related to treatment / all | 0 / 5 | 1 / 16 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetes mellitus inadequate control | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetic complication | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetic ketoacidosis | | | |
| subjects affected / exposed | 3 / 2996 (0.10%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 3 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetic metabolic decompensation | | | |
| subjects affected / exposed | 11 / 2996 (0.37%) | 18 / 2989 (0.60%) | |
| occurrences causally related to treatment / all | 1 / 12 | 0 / 18 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Electrolyte imbalance | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Fluid imbalance | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Fluid overload | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Food intolerance | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gout | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 5 / 2989 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 5 | 1 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypercalcaemia | | | |
| subjects affected / exposed | 2 / 2996 (0.07%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypercholesterolaemia | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypercreatininaemia | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyperglycaemia | | | |
| subjects affected / exposed | 4 / 2996 (0.13%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyperglycaemic hyperosmolar nonketotic syndrome | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Hyperinsulinaemic hypoglycaemia | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyperkalaemia | | | |
| subjects affected / exposed | 12 / 2996 (0.40%) | 20 / 2989 (0.67%) | |
| occurrences causally related to treatment / all | 1 / 13 | 1 / 21 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypernatraemia | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyperuricaemia | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 0 / 2989 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypoglycaemia | | | |
| subjects affected / exposed | 13 / 2996 (0.43%) | 7 / 2989 (0.23%) | |
| occurrences causally related to treatment / all | 6 / 13 | 3 / 8 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypokalaemia | | | |
| subjects affected / exposed | 5 / 2996 (0.17%) | 5 / 2989 (0.17%) | |
| occurrences causally related to treatment / all | 0 / 5 | 1 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyponatraemia | | | |

| | | | |
|---|------------------|-------------------|--|
| subjects affected / exposed | 3 / 2996 (0.10%) | 10 / 2989 (0.33%) | |
| occurrences causally related to treatment / all | 0 / 3 | 2 / 10 | |
| deaths causally related to treatment / all | 0 / 0 | 1 / 1 | |
| Hypophagia | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypovolaemia | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ketoacidosis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 3 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Ketosis | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 2 / 2989 (0.07%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lactic acidosis | | | |
| subjects affected / exposed | 1 / 2996 (0.03%) | 3 / 2989 (0.10%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metabolic acidosis | | | |
| subjects affected / exposed | 6 / 2996 (0.20%) | 11 / 2989 (0.37%) | |
| occurrences causally related to treatment / all | 2 / 7 | 2 / 13 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Obesity | | | |
| subjects affected / exposed | 0 / 2996 (0.00%) | 1 / 2989 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Type 2 diabetes mellitus | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 2 / 2996 (0.07%) | 4 / 2989 (0.13%) | |
| occurrences causally related to treatment / all | 0 / 2 | 1 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | 10 mg Empagliflozin | Placebo | |
|---|----------------------|----------------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 1191 / 2996 (39.75%) | 1274 / 2989 (42.62%) | |
| Injury, poisoning and procedural complications | | | |
| Fall | | | |
| subjects affected / exposed | 189 / 2996 (6.31%) | 193 / 2989 (6.46%) | |
| occurrences (all) | 215 | 234 | |
| Vascular disorders | | | |
| Hypertension | | | |
| subjects affected / exposed | 212 / 2996 (7.08%) | 248 / 2989 (8.30%) | |
| occurrences (all) | 245 | 281 | |
| Hypotension | | | |
| subjects affected / exposed | 212 / 2996 (7.08%) | 176 / 2989 (5.89%) | |
| occurrences (all) | 247 | 197 | |
| Cardiac disorders | | | |
| Atrial fibrillation | | | |
| subjects affected / exposed | 137 / 2996 (4.57%) | 156 / 2989 (5.22%) | |
| occurrences (all) | 154 | 177 | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 119 / 2996 (3.97%) | 164 / 2989 (5.49%) | |
| occurrences (all) | 133 | 176 | |
| Renal and urinary disorders | | | |
| Renal impairment | | | |
| subjects affected / exposed | 177 / 2996 (5.91%) | 181 / 2989 (6.06%) | |
| occurrences (all) | 201 | 197 | |
| Infections and infestations | | | |
| Urinary tract infection | | | |
| subjects affected / exposed | 207 / 2996 (6.91%) | 160 / 2989 (5.35%) | |
| occurrences (all) | 261 | 192 | |

| | | | |
|------------------------------------|--------------------|--------------------|--|
| Metabolism and nutrition disorders | | | |
| Diabetes mellitus | | | |
| subjects affected / exposed | 139 / 2996 (4.64%) | 200 / 2989 (6.69%) | |
| occurrences (all) | 150 | 219 | |
| Hyperkalaemia | | | |
| subjects affected / exposed | 170 / 2996 (5.67%) | 194 / 2989 (6.49%) | |
| occurrences (all) | 198 | 227 | |
| Hyperuricaemia | | | |
| subjects affected / exposed | 131 / 2996 (4.37%) | 208 / 2989 (6.96%) | |
| occurrences (all) | 140 | 222 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|------------------|--|
| 23 November 2017 | <p>The screening period was extended by 7 days. It was also clarified that screening procedures could be performed over multiple days.</p> <p>The exploratory secondary endpoint "first occurrence of sustained reduction of $\geq 40\%$ eGFR" was further specified.</p> <p>An Electrocardiogram (ECG) was to be performed at screening and not at the baseline visit.</p> <p>For laboratory analyses at screening, a haematology panel was added while urinalysis was removed.</p> <p>A national coordinator committee was set up to advise on the trial. An explanation was added to the protocol. The ketone monitoring strategy for patients with type 1 diabetes mellitus (T1DM) was added.</p> <p>The guidance to sites on the consent process for patients with T1DM was added.</p> |
| 19 July 2018 | <p>No major changes to the protocol were introduced by this amendment. The changes involved logistical or administrative aspects only and did not require independent ethics committee/institutional review board (IEC/IRB) approval (unless required by local regulations).</p> |
| 20 November 2019 | <p>The use of any Sodium-glucose co-transporter 2/1 (SGLT-2/1) inhibitors was allowed during the 30 day-period between the end-of-trial visit (EOT) and the follow-up visit occurring at study close-out.</p> <p>Changes to the planned analyses to be consistent with the changes introduced by the TSAP.</p> |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported